Cargando…

Nationwide multicenter study on the management of pulmonary neuroendocrine (carcinoid) tumors

BACKGROUND AND AIM: To analyze the management and outcome of patients with primary typical (TC) and atypical lung carcinoids (AC) in Switzerland. METHODS: Retrospective analysis of patients selected from a neuroendocrine tumor (NET) registry. Patients were divided into TC and AC according to patholo...

Descripción completa

Detalles Bibliográficos
Autores principales: Sadowski, Samira M, Christ, Emanuel, Bédat, Benoit, Kollár, Attila, Karenovics, Wolfram, Perren, Aurel, Triponez, Frédéric
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Bioscientifica Ltd 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5744629/
https://www.ncbi.nlm.nih.gov/pubmed/29229628
http://dx.doi.org/10.1530/EC-17-0271
_version_ 1783288784915267584
author Sadowski, Samira M
Christ, Emanuel
Bédat, Benoit
Kollár, Attila
Karenovics, Wolfram
Perren, Aurel
Triponez, Frédéric
author_facet Sadowski, Samira M
Christ, Emanuel
Bédat, Benoit
Kollár, Attila
Karenovics, Wolfram
Perren, Aurel
Triponez, Frédéric
author_sort Sadowski, Samira M
collection PubMed
description BACKGROUND AND AIM: To analyze the management and outcome of patients with primary typical (TC) and atypical lung carcinoids (AC) in Switzerland. METHODS: Retrospective analysis of patients selected from a neuroendocrine tumor (NET) registry. Patients were divided into TC and AC according to pathology reports, and surgical procedures were grouped as wedge/segmentectomy, lobectomy/bilobectomy and pneumectomy. Survival analysis was performed using the Kaplan–Meier method and log-rank test. RESULTS: Over 7 years, 113 pulmonary carcinoids (61.9% females, mean age 59.4 years) were included from 19 hospitals, with pathology data on Ki67 and necrosis incomplete in 16 cases. Eighty-three TC and 14 AC underwent surgical resection with a primary tumor size of median 14.5 (range 1–80) mm and diagnosis was established in 55.8% at surgery. Mean follow-up was 30.2 ± 23.1 months. Lobectomy was performed in 54.2% and wedge resection in 17.7% of cases. Six patients received additional systemic therapy. There was a trend for larger primary lesion size and a significantly higher rate of N2–N3 status in AC. Mean survival tended to be increased in patients with TC compared to AC (86.1 vs 48.4 months, P = 0.06) and mean disease-free interval after surgical resection was 74.1 and 48.3 months for TC and AC, respectively (P = 0.74). CONCLUSION: AC of the lung has a more malignant behavior and a trend to a worse outcome. The results of this registry reinforce the need for standardized histological diagnosis and inter-disciplinary therapeutic decision making to improve the quality of care of patients with TC and AC.
format Online
Article
Text
id pubmed-5744629
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Bioscientifica Ltd
record_format MEDLINE/PubMed
spelling pubmed-57446292018-01-04 Nationwide multicenter study on the management of pulmonary neuroendocrine (carcinoid) tumors Sadowski, Samira M Christ, Emanuel Bédat, Benoit Kollár, Attila Karenovics, Wolfram Perren, Aurel Triponez, Frédéric Endocr Connect Research BACKGROUND AND AIM: To analyze the management and outcome of patients with primary typical (TC) and atypical lung carcinoids (AC) in Switzerland. METHODS: Retrospective analysis of patients selected from a neuroendocrine tumor (NET) registry. Patients were divided into TC and AC according to pathology reports, and surgical procedures were grouped as wedge/segmentectomy, lobectomy/bilobectomy and pneumectomy. Survival analysis was performed using the Kaplan–Meier method and log-rank test. RESULTS: Over 7 years, 113 pulmonary carcinoids (61.9% females, mean age 59.4 years) were included from 19 hospitals, with pathology data on Ki67 and necrosis incomplete in 16 cases. Eighty-three TC and 14 AC underwent surgical resection with a primary tumor size of median 14.5 (range 1–80) mm and diagnosis was established in 55.8% at surgery. Mean follow-up was 30.2 ± 23.1 months. Lobectomy was performed in 54.2% and wedge resection in 17.7% of cases. Six patients received additional systemic therapy. There was a trend for larger primary lesion size and a significantly higher rate of N2–N3 status in AC. Mean survival tended to be increased in patients with TC compared to AC (86.1 vs 48.4 months, P = 0.06) and mean disease-free interval after surgical resection was 74.1 and 48.3 months for TC and AC, respectively (P = 0.74). CONCLUSION: AC of the lung has a more malignant behavior and a trend to a worse outcome. The results of this registry reinforce the need for standardized histological diagnosis and inter-disciplinary therapeutic decision making to improve the quality of care of patients with TC and AC. Bioscientifica Ltd 2017-11-08 /pmc/articles/PMC5744629/ /pubmed/29229628 http://dx.doi.org/10.1530/EC-17-0271 Text en © 2018 The authors http://creativecommons.org/licenses/by-nc/4.0/ This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) .
spellingShingle Research
Sadowski, Samira M
Christ, Emanuel
Bédat, Benoit
Kollár, Attila
Karenovics, Wolfram
Perren, Aurel
Triponez, Frédéric
Nationwide multicenter study on the management of pulmonary neuroendocrine (carcinoid) tumors
title Nationwide multicenter study on the management of pulmonary neuroendocrine (carcinoid) tumors
title_full Nationwide multicenter study on the management of pulmonary neuroendocrine (carcinoid) tumors
title_fullStr Nationwide multicenter study on the management of pulmonary neuroendocrine (carcinoid) tumors
title_full_unstemmed Nationwide multicenter study on the management of pulmonary neuroendocrine (carcinoid) tumors
title_short Nationwide multicenter study on the management of pulmonary neuroendocrine (carcinoid) tumors
title_sort nationwide multicenter study on the management of pulmonary neuroendocrine (carcinoid) tumors
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5744629/
https://www.ncbi.nlm.nih.gov/pubmed/29229628
http://dx.doi.org/10.1530/EC-17-0271
work_keys_str_mv AT sadowskisamiram nationwidemulticenterstudyonthemanagementofpulmonaryneuroendocrinecarcinoidtumors
AT christemanuel nationwidemulticenterstudyonthemanagementofpulmonaryneuroendocrinecarcinoidtumors
AT bedatbenoit nationwidemulticenterstudyonthemanagementofpulmonaryneuroendocrinecarcinoidtumors
AT kollarattila nationwidemulticenterstudyonthemanagementofpulmonaryneuroendocrinecarcinoidtumors
AT karenovicswolfram nationwidemulticenterstudyonthemanagementofpulmonaryneuroendocrinecarcinoidtumors
AT perrenaurel nationwidemulticenterstudyonthemanagementofpulmonaryneuroendocrinecarcinoidtumors
AT triponezfrederic nationwidemulticenterstudyonthemanagementofpulmonaryneuroendocrinecarcinoidtumors
AT nationwidemulticenterstudyonthemanagementofpulmonaryneuroendocrinecarcinoidtumors